Julie Mak
YOU?
Author Swipe
View article: Cancer Risk Reduction Strategies for Transgender, Non-Binary, and Gender-Diverse People With Hereditary Cancer Syndromes
Cancer Risk Reduction Strategies for Transgender, Non-Binary, and Gender-Diverse People With Hereditary Cancer Syndromes Open
Approximately 24 million people in the United States identify as transgender, non-binary, or gender-diverse, and they often face challenges in accessing health care related to education, employment, and economic circumstances. In addition,…
View article: NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024 Open
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic/likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and…
View article: Casting a Wide Net While Building a Safety Net: Addressing Disparities in Genetic Testing for Hereditary Cancer
Casting a Wide Net While Building a Safety Net: Addressing Disparities in Genetic Testing for Hereditary Cancer Open
View article: P535: Validation and real-life experience of a comprehensive, targeted next-generation sequencing panel for hereditary cancer predisposition
P535: Validation and real-life experience of a comprehensive, targeted next-generation sequencing panel for hereditary cancer predisposition Open
View article: An exploration in pitfalls in interpreting <scp>SDHB</scp> immunohistochemistry
An exploration in pitfalls in interpreting <span>SDHB</span> immunohistochemistry Open
Aims Mutations and epimutations in genes encoding the succinate dehydrogenase complex ( SDHx ) are associated with multiple tumour types in which identification of SDH‐deficiency has significant management implications. Immunohistochemistr…
View article: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology Open
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic canc…
View article: NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020 Open
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who…